MX2022008073A - Anticuerpos dirigidos a los huesos. - Google Patents

Anticuerpos dirigidos a los huesos.

Info

Publication number
MX2022008073A
MX2022008073A MX2022008073A MX2022008073A MX2022008073A MX 2022008073 A MX2022008073 A MX 2022008073A MX 2022008073 A MX2022008073 A MX 2022008073A MX 2022008073 A MX2022008073 A MX 2022008073A MX 2022008073 A MX2022008073 A MX 2022008073A
Authority
MX
Mexico
Prior art keywords
bone
antibodies
targeting antibodies
fragments
poly
Prior art date
Application number
MX2022008073A
Other languages
English (en)
Inventor
Huawei Qiu
Sunghae Park
James Stefano
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of MX2022008073A publication Critical patent/MX2022008073A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Abstract

Se proporcionan anticuerpos recombinantes y conjugados químicamente y fragmentos de los mismos modificados con uno o más péptidos poli-aspartato (poli-D) (p. ej., una secuencia D10) para mejorar la localización de los anticuerpos o fragmentos en hueso. También se describen métodos de fabricación y uso de estos anticuerpos y fragmentos.
MX2022008073A 2017-01-20 2019-07-17 Anticuerpos dirigidos a los huesos. MX2022008073A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762448763P 2017-01-20 2017-01-20

Publications (1)

Publication Number Publication Date
MX2022008073A true MX2022008073A (es) 2022-07-27

Family

ID=61581744

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019008549A MX2019008549A (es) 2017-01-20 2018-01-19 Anticuerpos dirigidos a los huesos.
MX2022008073A MX2022008073A (es) 2017-01-20 2019-07-17 Anticuerpos dirigidos a los huesos.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2019008549A MX2019008549A (es) 2017-01-20 2018-01-19 Anticuerpos dirigidos a los huesos.

Country Status (17)

Country Link
US (2) US10844115B2 (es)
EP (1) EP3571226A2 (es)
JP (2) JP7227138B2 (es)
KR (2) KR102613463B1 (es)
CN (1) CN111032690B (es)
AR (1) AR110755A1 (es)
AU (1) AU2018210270A1 (es)
BR (1) BR112019013986A2 (es)
CA (1) CA3050884A1 (es)
IL (1) IL268114A (es)
MX (2) MX2019008549A (es)
MY (1) MY194819A (es)
SG (1) SG11201906663VA (es)
TW (1) TWI788321B (es)
UY (1) UY37576A (es)
WO (1) WO2018136698A2 (es)
ZA (1) ZA201907673B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019533003A (ja) * 2016-08-11 2019-11-14 プレシセラ，インコーポレイテッド ＴＧＦ−βアンタゴニストコンジュゲート
KR20240018471A (ko) 2021-05-07 2024-02-13 베이롤 칼리지 오브 메드신 중등증 내지 중증 불완전 골형성증의 치료
WO2023004348A1 (en) * 2021-07-20 2023-01-26 William Marsh Rice University Engineered compositions for bone-targeted therapy
WO2023077131A1 (en) 2021-11-01 2023-05-04 Genzyme Corporation Treatment of osteogenesis imperfecta

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4867973A (en) 1984-08-31 1989-09-19 Cytogen Corporation Antibody-therapeutic agent conjugates
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US5571714A (en) 1988-12-22 1996-11-05 Celtrix Pharmaceuticals, Inc. Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use
AU690528B2 (en) 1992-12-04 1998-04-30 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
US5824655A (en) 1995-02-15 1998-10-20 The University Of Utah Anti-transforming growth factor-β gene therapy
GB9601081D0 (en) 1995-10-06 1996-03-20 Cambridge Antibody Tech Specific binding members for human transforming growth factor beta;materials and methods
HU228630B1 (en) 1996-02-09 2013-04-29 Abbott Biotech Ltd Use of human anti bodies that bind human tnf-alpha and process for inhibiting of human tnf-alpha activity
WO1998035703A2 (en) 1997-02-14 1998-08-20 The Salk Institute For Biological Studies Methods and compositions for delivery of therapeutic agents to bone tissue employing conjugates of negatively charged peptide oligomers with therapeutic agents
EP1074563A1 (en) * 1999-08-02 2001-02-07 F. Hoffmann-La Roche Ag Chimeric polypeptides enhancing dimer formation through electrostatic interactions and disulfide bond, method for production and uses thereof
US20030224501A1 (en) 2000-03-17 2003-12-04 Young Paul E. Bone morphogenic protein polynucleotides, polypeptides, and antibodies
NZ571243A (en) 2002-12-31 2010-04-30 Altus Pharmaceuticals Inc Complexes of protein crystals and ionic polymers comprising human growth hormone and protamine
WO2004098637A1 (en) 2003-04-30 2004-11-18 Genzyme Corporation Tgf-beta antagonists combined with renin-angiotensin-aldosteron-system antagonists for treating renal insufficiency
EP1646655A2 (en) 2003-07-09 2006-04-19 Eli Lilly And Company Tgf-beta1 ligands
ZA200608130B (en) 2004-03-31 2008-12-31 Genentech Inc Humanized anti-TGF-beta antibodies
EP3404102B1 (en) 2004-04-21 2021-08-11 Alexion Pharmaceuticals, Inc. Bone delivery conjugates and method of using same to target proteins to bone
TR201901929T4 (tr) 2005-02-08 2019-03-21 Genzyme Corp TGFBeta'ya antikorlar.
TW200714289A (en) * 2005-02-28 2007-04-16 Genentech Inc Treatment of bone disorders
GEP20156390B (en) 2008-01-03 2015-11-10 Scripps Research Inst Antibody targeting through a modular recognition domain
US8574577B2 (en) * 2008-01-03 2013-11-05 The Scripps Research Institute VEGF antibodies comprising modular recognition domains
DK2350129T3 (en) 2008-08-25 2015-08-31 Amplimmune Inc PREPARATIONS WITH PD-1 ANTAGONISTS AND PROCEDURES FOR USE THEREOF
JP5714505B2 (ja) 2008-12-22 2015-05-07 ノヴォ ノルディスク アー／エス 組織因子経路阻害因子に対する抗体
WO2010124276A2 (en) 2009-04-24 2010-10-28 Vanderbilt Universtiy Anti-tgf-beta induction of bone cell function and bone growth
PL2542590T5 (pl) 2010-03-05 2020-08-10 The Johns Hopkins University Kompozycje i sposoby dla ukierunkowanych immunomodulatorowych przeciwciał i białek fuzyjnych
HUE037651T2 (hu) 2011-04-20 2018-09-28 Medimmune Llc B7-Hl-et és PD-l-et kötõ ellenanyagok és más molekulák
SG10201902706VA (en) 2011-06-03 2019-04-29 Xoma Technology Ltd Antibodies specific for tgf-beta
CN108892726A (zh) 2011-06-13 2018-11-27 艾比吉诺米克斯合作公司 抗psgl-1抗体及其用途
WO2013058833A1 (en) 2011-10-19 2013-04-25 Enobia Canada Limited Partnership Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
US10052366B2 (en) * 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
EP2855527B1 (en) 2012-05-31 2018-08-01 Innate Pharma Tlr3 binding agents
US9682143B2 (en) 2012-08-14 2017-06-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
AU2013331154B2 (en) 2012-10-17 2018-02-01 Cedars-Sinai Medical Center Molecular signatures of ovarian cancer
DK3312195T3 (da) * 2013-03-20 2020-01-06 Genzyme Corp Fremgangsmåder til behandling af osteogenesis imperfecta
LT2981822T (lt) 2013-05-06 2020-12-28 Scholar Rock, Inc. Kompozicijos ir būdai, skirti augimo faktoriaus moduliacijai
HUE049281T2 (hu) 2013-09-13 2020-09-28 Beigene Switzerland Gmbh Anti-PD1 antitestek, valamint terapeutikumként és diagnosztikumként történõ alkalmazásuk
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
US20170216401A1 (en) 2014-03-17 2017-08-03 Piotr Jachimczak Combination for use in a method of treating cancer
CN107428825A (zh) 2014-10-10 2017-12-01 创祐生技股份有限公司 治疗及/或预防肿瘤生长、侵袭及/或转移的方法
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
WO2016123573A1 (en) 2015-01-30 2016-08-04 President And Fellows Of Harvard College Peritumoral and intratumoral materials for cancer therapy
EA201792273A1 (ru) 2015-04-17 2018-04-30 Бристол-Маерс Сквибб Компани Композиции, содержащие комбинацию анти-pd-1 антитела и другого антитела
WO2017011773A2 (en) 2015-07-15 2017-01-19 Modernatx, Inc. Codon-optimized nucleic acids encoding antibodies
CA2996996A1 (en) 2015-08-31 2017-03-09 National Research Council Of Canada Tgf-.beta.-receptor ectodomain fusion molecules and uses thereof
JP2019533003A (ja) 2016-08-11 2019-11-14 プレシセラ，インコーポレイテッド ＴＧＦ−βアンタゴニストコンジュゲート

Also Published As

Publication number Publication date
US10844115B2 (en) 2020-11-24
AU2018210270A1 (en) 2019-09-05
CA3050884A1 (en) 2018-07-26
JP2023058590A (ja) 2023-04-25
KR102613463B1 (ko) 2023-12-15
BR112019013986A2 (pt) 2020-03-03
TW202330597A (zh) 2023-08-01
TWI788321B (zh) 2023-01-01
AR110755A1 (es) 2019-05-02
KR20230172039A (ko) 2023-12-21
ZA201907673B (en) 2021-05-26
RU2019126026A (ru) 2021-02-20
WO2018136698A3 (en) 2018-08-30
UY37576A (es) 2018-10-31
WO2018136698A2 (en) 2018-07-26
SG11201906663VA (en) 2019-08-27
TW201839013A (zh) 2018-11-01
US20210163584A1 (en) 2021-06-03
RU2019126026A3 (es) 2021-11-09
JP7227138B2 (ja) 2023-02-21
JP2020505919A (ja) 2020-02-27
IL268114A (en) 2019-09-26
CN111032690A (zh) 2020-04-17
KR20190105236A (ko) 2019-09-16
US20180208650A1 (en) 2018-07-26
EP3571226A2 (en) 2019-11-27
CN111032690B (zh) 2024-03-26
MY194819A (en) 2022-12-17
MX2019008549A (es) 2019-09-11

Similar Documents

Publication Publication Date Title
MX2022008073A (es) Anticuerpos dirigidos a los huesos.
AU2019284081A1 (en) Food compositions comprising recombinant milk proteins and methods of producing the same
MX2016017311A (es) Composiciones de portador-anticuerpo y metodos para realizarlas y utilizarlas.
PH12018501281A1 (en) Human immunodeficiency virus neutralizing antibodies
ZA201904725B (en) Personalised immunogenic peptide identification platform
MX2022005291A (es) Vacunas para el tratamiento y prevencion del cancer.
GEP20217326B (en) Constructs having a sirp-alpha domain or variant thereof
MX2020004073A (es) Procesos de siembra en serie y usos de los mismos.
MX2019007020A (es) Anticuerpos il-11.
MX2018014456A (es) Anticuerpos contra alfa-sinucleina y sus usos.
PH12017502207A1 (en) Tau-binding antibodies
MX2016002937A (es) Vacuna oncologica.
MX2021001460A (es) Metodos y composiciones para secrecion de polipeptidos heterologos.
MX2019003970A (es) Péptidos de arginasa inmunogénicos.
EP4219540A3 (en) Ctla-4 variant immunomodulatory proteins and uses thereof
MY182046A (en) Interferon alpha and omega antibody antagonists
MY194084A (en) Interferon beta antibodies and uses thereof
MY195726A (en) Steviol Glycoside Transport
SG11202001602QA (en) Peptide conjugates, conjugation process, and uses thereof
MX2018000023A (es) Particulas semejantes a virus recombinantes que utilizan la proteina gag del virus de inmunodeficiencia bovina.
PH12019502449A1 (en) Anti-jagged1 antigen binding proteins
PH12018500468A1 (en) Fusion protein
MX2021015766A (es) Nuevos antigenos y metodos contra el cancer.
SG11201907914QA (en) Polypeptide, polypeptide fragment, derivative thereof, and applications thereof
AU2017305946A8 (en) C1q and HMGB1 fusion proteins and uses thereof